14 research outputs found
Infection and coinfection by human papillomavirus, Epstein–Barr virus and Merkel cell polyomavirus in patients with squamous cell carcinoma of the larynx: a retrospective study
Background Human papillomavirus (HPV) is recognized as an important risk factor for laryngeal carcinogenesis. Although HPV-16 and 18 have been strongly implicated, the presence of other high-risk HPV (HR-HPV) genotypes or the coinfection with Epstein-Barr virus (EBV) or Merkel cell polyomavirus (MCPV) may increase the risk, but their etiological association has not been definitively established. Methods We characterized the genotype-specific HPV and the frequency of EBV and MCPV infections through the detection of their DNA in 195 laryngeal specimens of squamous cell carcinoma (SCC) histologically confirmed. Results HPV DNA was detected in 93 (47.7%) specimens. HPV-11 was the most frequent with 68 cases (73.1%), and HPV-52 was the most frequently HR-HPV found with 51 cases, which corresponds to 54.8% of all HPV-positive specimens. EBV DNA was detected in 54 (27.7%) tumor tissue specimens of which 25 (46.3%) were in coinfection with HPV. MCPV DNA was detected only in 11 (5.6%) cases of which 5 (45.4%) were in coinfection with an HR-HPV. No association between the presence of DNA of the three examined viruses and the patient smoking habits, alcohol consumption, age, the keratinization status, differentiation grade, or localization of the tumor in the larynx were found. Discussion HPV-52 was the most prevalent HR-HPV, which may suggest that this and other genotypes in addition to HPV-16 and 18 could be considered for prophylaxis. However, further studies including non-cancer larynx cases and the evaluation of other molecular markers and viral co-infection mechanisms are needed to determine the role of the different HR-HPV genotypes, EBV, and MCPV in the etiology of SCC of the larynx
SÃndrome agudo respiratorio severo: un panorama mundial de la epidemia
A principios de febrero de 2003 la Organización Mundial de la Salud comenzó a recibir reportes de pacientes con un sÃndrome caracterizado por neumonÃa atÃpica, con rápida progresión hacia insuficiencia respiratoria sin una causa identificada. Los casos aparentemente se iniciaron en el sur de China y se han diseminado a otras regiones en Asia, Europa, Sudáfrica, Norte América y Sur América. La causa de este sÃndrome es una nueva variedad de Coronavirus, aislado en secreciones respiratorias y en otras. El sÃndrome ha sido definido en inglés como SARS (Severe acute respiratory syndrome) por la Organización Mundial de la Salud y se caracteriza por un periodo de incubación de 1 a 10 dÃas (promedio de cinco dÃas), una fase febril prodrómica que aparece entre los dÃas 1 a 3. Posteriormente, aparecen sÃntomas respiratorios como tos, disnea, y signos como hipoxemia, que en 10 a 40% de los casos requieren de ventilación mecánica. La tasa de letalidad ha variado de 3% hasta 16%. Los hallazgos de laboratorio incluyen trombocitopenia, leucopenia, elevación de creatinin-fosfokinasa, y, en ocasiones, de transaminasas hepáticas y deshidrogenasa láctica. El tratamiento incluye medidas de apoyo; la utilización empÃrica del antiviral ribavirina es controvertida, debido a que hasta el momento no existe un tratamiento especÃfico. Se recomienda el aislamiento respiratorio de los pacientes, la utilización de máscaras protectoras y el lavado estricto de manos como principales medidas de prevención. Desde el inicio de esta epidemia México estableció un sistema de vigilancia, asà como recomendaciones al personal de salud para la identificación, prevención de casos secundarios y manejo clÃnico de casos sospechosos. El texto completo en inglés de este artÃculo está disponible en: http://www.insp.mx/salud/index.htm
SÃndrome agudo respiratorio severo: un panorama mundial de la epidemia Severe acute respiratory syndrome: a global view of the epidemic
A principios de febrero de 2003 la Organización Mundial de la Salud comenzó a recibir reportes de pacientes con un sÃndrome caracterizado por neumonÃa atÃpica, con rápida progresión hacia insuficiencia respiratoria sin una causa identificada. Los casos aparentemente se iniciaron en el sur de China y se han diseminado a otras regiones en Asia, Europa, Sudáfrica, Norte América y Sur América. La causa de este sÃndrome es una nueva variedad de Coronavirus, aislado en secreciones respiratorias y en otras. El sÃndrome ha sido definido en inglés como SARS (Severe acute respiratory syndrome) por la Organización Mundial de la Salud y se caracteriza por un periodo de incubación de 1 a 10 dÃas (promedio de cinco dÃas), una fase febril prodrómica que aparece entre los dÃas 1 a 3. Posteriormente, aparecen sÃntomas respiratorios como tos, disnea, y signos como hipoxemia, que en 10 a 40% de los casos requieren de ventilación mecánica. La tasa de letalidad ha variado de 3% hasta 16%. Los hallazgos de laboratorio incluyen trombocitopenia, leucopenia, elevación de creatinin-fosfokinasa, y, en ocasiones, de transaminasas hepáticas y deshidrogenasa láctica. El tratamiento incluye medidas de apoyo; la utilización empÃrica del antiviral ribavirina es controvertida, debido a que hasta el momento no existe un tratamiento especÃfico. Se recomienda el aislamiento respiratorio de los pacientes, la utilización de máscaras protectoras y el lavado estricto de manos como principales medidas de prevención. Desde el inicio de esta epidemia México estableció un sistema de vigilancia, asà como recomendaciones al personal de salud para la identificación, prevención de casos secundarios y manejo clÃnico de casos sospechosos.In early February 2003, the World Health Organization (WHO) began receiving reports of patients with a syndrome characterized by an atypical pneumonia with rapid progression to respiratory failure without an identified cause despite extensive diagnostic workups. Most of these reports pointed out that the outbreak started in Southern China, specifically in the Guandong Province. The initial outbreak in South East Asia has already spread to other Regions in Asia, Europe, North and South America, and South Africa. Many of these cases can be linked through chains of transmission to an index case from the Guandong Province who visited Hong Kong. Although the exact mode of transmission has not been clearly established, the etiology of this syndrome has already been identified. A novel Coronavirus has been identified by electron microscopy and molecular assays in multiple laboratories from respiratory specimens throughout the world. The syndrome has been defined as SARS (Severe Acute Respiratory Syndrome) by WHO, and is characterized by an incubation period between 1 and 10 days (average 5 days) and by a febrile phase that usually lasts approximately 3 days. During the respiratory phase that begins around day 3, patients start developing a dry cough, shortness of breath and hypoxemia. Mechanical ventilatory support is required in about 10 to 40% of cases and the case-fatality rate ranges between 3 and 16%. The laboratory findings in SARS cases include leukopenia, thrombocytopenia, and a rise in transaminases and lactic dehydrogenase levels. Treatment of SARS includes supportive measures and the empiric use of ribavirin. Respiratory isolation, use of respiratory masks, and compulsory hand hygiene constitute the principal preventive measures. The confirmation of a case can be performed at reference laboratories by serologic and molecular assays. From the onset of this epidemic Mexico established a surveillance system as well as clinical guidelines and recommendations for the identification, prevention of secondary spread, and medical management of suspicious and probable cases by health care personnel
Hospital triage system for adult patients using an influenza-like illness scoring system during the 2009 pandemic--Mexico.
Pandemic influenza A (H1N1) virus emerged during 2009. To help clinicians triage adults with acute respiratory illness, a scoring system for influenza-like illness (ILI) was implemented at Hospital Civil de Guadalajara, Mexico.A medical history, laboratory and radiology results were collected on emergency room (ER) patients with acute respiratory illness to calculate an ILI-score. Patients were evaluated for admission by their ILI-score and clinicians' assessment of risk for developing complications. Nasal and throat swabs were collected from intermediate and high-risk patients for influenza testing by RT-PCR. The disposition and ILI-score of those oseltamivir-treated versus untreated, clinical characteristics of 2009 pandemic influenza A (H1N1) patients versus test-negative patients were compared by Pearson's Chi(2), Fisher's Exact, and Wilcoxon rank-sum tests.Of 1840 ER patients, 230 were initially hospitalized (mean ILI-score = 15), and the rest were discharged, including 286 ambulatory patients given oseltamivir (median ILI-score = 11), and 1324 untreated (median ILI-score = 5). Fourteen (1%) untreated patients returned, and 3 were hospitalized on oseltamivir (median ILI-score = 19). Of 371 patients tested by RT-PCR, 104 (28%) had pandemic influenza and 42 (11%) had seasonal influenza A detected. Twenty (91%) of 22 imaged hospitalized pandemic influenza patients had bilateral infiltrates compared to 23 (38%) of 61 imaged hospital test-negative patients (p<0.001). One patient with confirmed pandemic influenza presented 6 days after symptom onset, required mechanical ventilation, and died.The triaging system that used an ILI-score complimented clinicians' judgment of who needed oseltamivir and inpatient care and helped hospital staff manage a surge in demand for services
Histogram of patients seeking care for acute respiratory infections at Hospital Civil de Guadalajara during the (H1N1) pandemic 2009—Mexico.
<p>Histogram of patients seeking care for acute respiratory infections at Hospital Civil de Guadalajara during the (H1N1) pandemic 2009—Mexico.</p
Demographic Characteristics of Patients Seeking Care for acute respiratory infection at the Hospital Civil de Guadalajara during the (H1N1) pandemic 2009—Mexico.
<p>*Difference between seasonal influenza and pandemic (H1N1), 2009, p = 0.0007.</p><p>¥2% of pandemic (H1N1) 2009 missing risk assessment information.</p><p>‡Includes all hospitalized cases regardless of influenza RT-PCR test results.</p><p>∞Includes all hospitalized cases and ambulatory patients treated with oseltamivir who tested positive for influenza A.</p
Influenza Scoring System at the Hospital Civil de Guadalajara during the (H1N1) pandemic 2009—Mexico<sub>‡</sub>.
<p>Influenza Scoring System at the Hospital Civil de Guadalajara during the (H1N1) pandemic 2009—Mexico<sub>‡</sub>.</p
Typical radiological findings of Pandemic (H1N1) 2009 patient at the Hospital Civil de Guadalajara—Mexico.
<p>Typical radiological findings of Pandemic (H1N1) 2009 patient at the Hospital Civil de Guadalajara—Mexico.</p
Patients seeking care with acute respiratory infections at the Hospital Civil de Guadalajara during the (H1N1) pandemic 2009—Mexico.
<p>Patients seeking care with acute respiratory infections at the Hospital Civil de Guadalajara during the (H1N1) pandemic 2009—Mexico.</p